✦ LIBER ✦

AUSTRALIA ANTIBODIES IN PATIENTS WITH ACUTE RENAL INSUFFICIENCY UNDERGOING HÆMODIALYSIS

✍ Scribed by Milcov, V; Babes, V.T; Sandu, L; Cajal, S

Book ID: 123040234
Publisher: The Lancet
Year: 1973
Tongue: English
Weight: 159 KB
Volume: 302
Category: Article
ISSN: 0140-6736
DOI: 10.1016/S0140-6736(73)93303-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Procalcitonin in patients with acute and

Procalcitonin in patients with acute and chronic renal insufficiency

✍ Gerald Steinbach; Edwin Bölke; Adolf Grünert; Klaus Orth; Martin Störck 📂 Article 📅 2004 🏛 Springer Vienna 🌐 English ⚖ 95 KB

Pharmacokinetics of Aliskiren in Patient

Pharmacokinetics of Aliskiren in Patients with End-Stage Renal Disease Undergoing Haemodialysis

✍ Dmytro Khadzhynov, Torsten Slowinski, Ina Lieker, Hans-Hellmut Neumayer, Diego A 📂 Article 📅 2012 🏛 Springer International Publishing AG 🌐 English ⚖ 435 KB

High prevalence of renal artery stenosis

High prevalence of renal artery stenosis in patients with renal insufficiency undergoing coronary angiography

✍ George W. Vetrovec; Ravinder S. Kohli; Sharon E. Cole; Stephen A. Lewis 📂 Article 📅 1990 🏛 Elsevier Science 🌐 English ⚖ 271 KB

Enoxaparin in patients with renal insuff

Enoxaparin in patients with renal insufficiency presenting with acute coronary syndromes

✍ Michael J. Greenwood; John Atherton; Justin Westhuyzen; Erika Tapp; John Rowell; 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 142 KB

Contrast-induced nephropathy in patients

Contrast-induced nephropathy in patients with renal insufficiency undergoing contrast-enhanced MDCT

✍ Murakami, Ryusuke; Hayashi, Hiromitsu; Sugizaki, Ken-ichi; Yoshida, Tamiko; Okaz 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 143 KB

Oral pharmacokinetics of pirenzepine in

Oral pharmacokinetics of pirenzepine in patients with chronic renal insufficiency, failure, and maintenance haemodialysis

✍ T. MacGregor; K. Matzek; J. Keirns; M. Vinocur; A. Chonko 📂 Article 📅 1990 🏛 Springer 🌐 English ⚖ 215 KB

The pharmacokinetic properties of pirenzepine following administration of a single, 50 mg oral dose were evaluated in three groups of subjects: group I, end stage renal disease requiring maintenance haemodialysis (CLCR 0 to 10 ml.min-1); group II, moderate renal insufficiency (CLCR 10 to 30 ml.min-1